Bioxydyn is the world leader in providing oxygen-enhanced MRI (OE-MRI). OE-MRI is a non-invasive and non-ionising imaging method that provides information on lung disease status and tissue oxygenation. We have developed patented approaches for characterising lung physiology in diseases such as COPD and asthma, and tissue oxygenation status in cancer. Our methods are applied in clinical therapeutic trials and are being developed as groundbreaking diagnostic tools.
OE-MRI is a powerful yet easily accessible technology. Standard MRI scanners are used with minimal additional equipment to provide a convenient, non-invasive, non-ionising and rapid assessment.
OE-MRI for lung disease
Standard lung function tests such as spirometry are not sufficiently sensitive or precise and provide no information on regional lung function. To help fill this gap, imaging techniques are becoming increasingly important in managing lung disease. X-ray CT is a useful diagnostic method but radiation exposure and the inability of CT to characterise lung function limit its use. SPECT and scintigraphy also require ionising radiation and suffer from poor resolution, while other MRI based techniques are too complex and costly to play a practical role in clinics. Bioxydyn’s patented oxygen-enhanced MRI (OE-MRI) methods can be applied easily in Radiology Departments. They are unique as they provide the lung physician with the only repeatable, non-ionising, non-invasive quantitative solution for characterising the physiological impact of regional lung disease.
Bioxydyn’s pioneering OE-MRI imaging capabilities use oxygen as an MR imaging agent, which is delivered to the patient in the scanner. OE-MRI allows us to monitor the delivery of oxygen to the patient's lung exchange tissues. The acquired signals are subject to proprietary analysis and modelling techniques to generate quantitative imaging biomarkers relating to regional lung perfusion and ventilation.
OE-MRI for oncology
OE-MRI can also be applied outside the lung using simiilar methods as described above. Transport of oxygen can be monitored in the major arteries, and at delivery to tissues around the body. This is of particular relevance in cancer, where tissue oxygenation levels have an impact on disease progression and on response to therapy. Recently published work demonstrates the potential of the method for identifying tumour hypoxia.